2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Value, Diseases, Bleeding and Clotting, Immunology, Infectious Diseases, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1619 External validation of an electronic health-related social needs assessment for survival in patients with newly diagnosed and treated acute myeloid leukemia

Michelle Hyunju Lee, MD, Angela Tramontano, MS2, Shanee Yamnitsky, BA3, Evelyn Chen, BS4, Donian Chyong, BA5, Brandon James Aubrey, MBBS PhD FRACP FRCPA6, Philip Amrein, MD7, Andrew M Brunner, MD8, Hanno Hock, MD, PhD9, Rupa Narayan, MD10, Nathanael Fillmore, PhD11, Areej R El-Jawahri, MD12, Elyse R Park, PhD13, Jennifer La, PhD14, Amir T. Fathi, MD15, Clark Dumontier, MD, MPH16, Gabriela Soriano Hobbs, MD17
1 Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, United States
2 Dana Farber Cancer Institute, Boston, Massachusetts, United States
3 Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, United States
4 Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, United States
5 University of Vermont, Burlington, Vermont, United States
6 Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, United States
7 Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, United States
8 Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, United States
9 Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, United States
10 Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, United States
11 Boston Veterans Affairs Healthcare System, Jamaica Plain, United States
12 Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, United States
13 Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, United States
14 Boston Veterans Affairs Healthcare System, Jamaica Plain, United States
15 Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, United States
16 Boston Veterans Affairs Healthcare System, Jamaica Plain, United States, Dana Farber Cancer Institute, Boston, Massachusetts, United States
17 Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, United States
Introduction: Health-related social needs (HRSN) adversely affect outcomes in acute myeloid leukemia (AML) yet are rarely captured systematically due to a lack of practical screening tools. To address this gap, we developed eMAPS (electronic Mobility And PsychoSocial score). eMAPS includes 13 extractable covariates chosen as proxy for housing security, financial security, access to food and transportation, social and caregiver support, work support, and neighborhood and community safety—HRSN domains recognized by the National Comprehensive Cancer Network as screening priorities. In our derivation cohort of veterans with AML treated within the Veterans Health Administration (VA), higher eMAPS was associated with higher hazard of death, particularly among patients induced with venetoclax combinations (Lee et al., Blood 2025). Here, we aimed to externally validate eMAPS in an independent, non-VA population.

Methods: The validation cohort consisted of AML patients ≥18 years newly diagnosed and treated at the Massachusetts General Hospital between 06/2016-09/2024. As with the eMAPS derivation study, we included patients induced with either cytarabine-based intensive chemotherapy (IC) or venetoclax combinations (VC). Variables for eMAPS included unstable housing, limited socioeconomic support, rural residence based on Rural-Urban Commuting Area (RUCA) codes, area deprivation index (ADI) of 6-10 (versus [vs] 1-5), body mass index (BMI) ≥30 kg/m2, unmarried status, unemployment history, limited mobility, home oxygen dependence, substance use disorder, mental disorder, tobacco dependence, and area-level household income below the median. A score was calculated for each patient based on the presence (1-point [pt]) or absence (0 pts) of each measure at the time of AML diagnosis, with 13 pts indicating highest vulnerability. Missing variables due to lack of EHR documentation were assigned a 0. The primary outcome was overall survival (OS) estimated by Kaplan-Meier; Cox proportional hazard models were used to assess the association of increasing eMAPS score with OS, adjusting for age, sex, risk, transplant status, induction type (IC vs VC), and EuropeanLeukemia Net (ELN) 2022 risk stratification. Prognostic model discrimination was assessed via Uno’s concordance statistic (C-statistic).

Results: Among 383 patients, 234 (61%) were treated with IC and 149 (39%) with VC. The median age was 68 years (interquartile range [IQR]: 57-75), 88% were White, and 61% were male. Most patients (71%) presented with adverse risk AML by the ELN 2022 criteria with 22% harboring a TP53 mutation. 113 patients (29.5%) had a prior myeloid neoplasm, and 39 (10%) received hypomethylating agents prior to AML diagnosis.

The median eMAPS score of our validation cohort was 3 (IQR: 2-5) compared to 4 (IQR: 2-5) in the derivation cohort. Forty-eight patients (12.5%) had an eMAPS score ≥6. The most prevalent domains included neighborhood disadvantage by ADI (51%), tobacco dependence (51%), and unmarried status (37%). At a median follow-up of 16 months (IQR: 4.6-40), the median OS was 19.7 months (IQR: 14.6-26.5). In the multivariable Cox model, every 1-point increase in eMAPS was associated with a 10% increased hazard of death (HR=1.1, 95% confidence interval [CI]: 1.01-1.19). A C-statistic model of eMAPS demonstrated comparable discrimination for OS (0.70, 95% CI: 0.67-0.73) as models including ELN risk alone (0.73, 95% CI: 0.71-0.74). 

Conclusion: This study externally validates eMAPS as a prognostic tool in AML, demonstrating consistent association between higher HRSN burden and increased hazard of death in an independent non-VA cohort. With concordance statistics, eMAPS discriminated OS with accuracy comparable to the ELN 2022 classification model. As an entirely electronic health records-derived assessment, eMAPS offers a pragmatic and scalable approach to systematic HRSN screening that merits prospective evaluation alongside genetic risk in treatment decision-making for AML.

Michelle Hyunju Lee, MD: Daiichi Sankyo - Honoraria; Incyte - Honoraria; Novartis - Honoraria; Takeda - Honoraria; Geron - Honoraria; Syndax - Research Funding; PharmaEssentia - Research Funding; PharmaEssentia - Consultancy (Includes expert testimony)